Alzamend Neuro, Inc. Short Interest Update
ALZN Stock | USD 1.19 0.03 2.59% |
About 55% of Alzamend Neuro's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Alzamend Neuro suggests that some traders are interested. Alzamend Neuro's investing sentiment overview a quick insight into current market opportunities from investing in Alzamend Neuro. Many technical investors use Alzamend Neuro stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Alzamend |
Alzamend Neuro, Inc. saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 103,200 shares, an increase of 47.9 percent from the September 15th total of 69,800 shares. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is currently 0.1
Read at thelincolnianonline.com
Alzamend Neuro Fundamental Analysis
We analyze Alzamend Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alzamend Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alzamend Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Alzamend Neuro is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Alzamend Neuro Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alzamend Neuro stock to make a market-neutral strategy. Peer analysis of Alzamend Neuro could also be used in its relative valuation, which is a method of valuing Alzamend Neuro by comparing valuation metrics with similar companies.
Peers
Alzamend Neuro Related Equities
SNTI | Senti Biosciences | 11.46 | ||||
XFOR | X4 Pharmaceuticals | 10.87 | ||||
ABOS | Acumen Pharmaceuticals | 2.48 | ||||
KZR | Kezar Life | 2.26 | ||||
ADVM | Adverum Biotechnologies | 1.62 | ||||
ALEC | Alector | 1.17 | ||||
DAWN | Day One | 1.13 | ||||
HOOK | Hookipa Pharma | 0.52 | ||||
SLDB | Solid Biosciences | 0.31 | ||||
ADAG | Adagene | 0.54 | ||||
INZY | Inozyme Pharma | 1.45 | ||||
TERN | Terns Pharmaceuticals | 1.56 | ||||
MOLN | Molecular Partners | 4.30 |
Check out Alzamend Neuro Hype Analysis, Alzamend Neuro Correlation and Alzamend Neuro Performance. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.